Statement 3.3

  • Section 3

"Before making a pharmacy preparation, the hospital pharmacist must undertake a risk assessment to determine the best practice quality requirements. These must consider premises, equipment, pharmaceutical knowledge and labelling."

What does it mean for patients? Not all injectable preparations can be prepared by the pharmacy. In such cases, hospital pharmacists have the competency to define safe procedures to be used by other healthcare professionals to avoid patient harm.

What does it mean for healthcare professionals? Not all injectable preparations can be prepared by the pharmacy. In such cases, hospital pharmacists should support other healthcare professionals, nurses and doctors by describing feasible procedures for safe and preparation and administration.

What does it mean for Hospital Pharmacists? Where it is not feasible for the hospital pharmacy to prepare such medicines e.g. they do not have aseptic facilities, then hospital pharmacists should be involved in ensuring there are appropriate policies and protocols in place for preparation to be undertaken safely at ward level. Only reconstitution considered low risk should be prepared at ward level. In addition the staff preparing the medicines should have received training and be competent to undertake reconstitution

Resources

Preview Title Document
OPTIMIZATION OF RISK MANAGEMENT OF DRUGS COLD CHAIN IN HOSPITAL BY FAILURE MODES, EFFECTS AND CRITICALITY ANALYSIS "FMECA" METHOD PDF icon OPTIMIZATION OF RISK MANAGEMENT OF DRUGS COLD CHAIN IN HOSPITAL BY FAILURE MODES, EFFECTS AND CRITICALITY ANALYSIS %22FMECA%22 METHOD.pdf
IMPLEMENTING A NATIONAL PORTFOLIO OF EXTEMPORANEOUS PHARMACEUTICAL PREPARATIONS USED IN DANISH HOSPITALS PDF icon Implementing a national portfolio of extemporaenours pharmaceutical preparations used in Danish hospitals.pdf
DEVELOPMENT OF NEW PRODUCTION WHEN NEITHER PACKAGING NOR SOME OF THE RAW MATERIALS CONFORM TO EUROPEAN STANDARDS PDF icon pc7160.pdf
HOW TO HANDLE ACTIVE AND PLACEBO DRUGS FOR A CLINICAL TRIAL IN THE PRODUCTION SYSTEM CATO IN ORDER TO SECURE THE BLIND AND TO ENSURE THE EXACT SAME PREPARATION OF ACTIVE AND PLACEBO PRODUCTS PDF icon pc7207.pdf
QUANTIFICATION OF WAITING TIME REDUCTION IN OUTPATIENT SETTING USING ASSISTED SYSTEMS IN AN AUTOMATED ONCOLOGY PHARMACY. PDF icon QUANTIFICATION OF WAITING TIME REDUCTION IN OUTPATIENT SETTING USING ASSISTED SYSTEMS IN AN AUTOMATED ONCOLOGY PHARMACY..pdf
Resolution CM/Res(2016)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients PDF icon resource statement 3.3-compunding.pdf
EJHP: Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution PDF icon resource statement 3.3.pdf
EAHP Survey results 2016/2017 (sections 1,3 and 4) PDF icon EAHP Survey Report 2016-17 .pdf
EAHP Survey Report 2015 PDF icon EAHP Survey report 2015.pdf
GPI:Implementing chemotherapy dose-banding using retrospective data analysis and exponential calculus PDF icon GPI 3.3-3.4.pdf

Pages